Hong Kong Stock Exchange · Healthcare
Invest in Shenzhen Hepalink Pharmaceutical Group stock from India
Indian and foreign residents can buy Shenzhen Hepalink Pharmaceutical Group (9989) shares directly through Paasa.
By Paasa · Updated
Shenzhen Hepalink Pharmaceutical Group at a glance
- Price
- HK$4.03+HK$0.08 (2.03%)
- Market cap
- HK$13.59B
- Day range
- HK$3.93 – HK$4.06
- P/E
- 70.63
- Dividend yield
- 1.47%
- Volume
- 610.00K
- 1 month
- -8.31%
- 6 months
- -18.02%
- YTD
- -22.74%
- 1 year
- -26.01%
- 5 years
- -52.37%
Shenzhen Hepalink Pharmaceutical Group statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CN¥5.5B | CN¥5.3B | CN¥5.4B | CN¥7.2B | CN¥6.4B |
| Gross profit | CN¥1.7B | CN¥1.8B | CN¥1.8B | CN¥2.3B | CN¥2.0B |
| Operating income | CN¥636.0M | CN¥741.3M | −CN¥238.1M | CN¥1.1B | CN¥773.2M |
| Net income | CN¥349.5M | CN¥646.7M | −CN¥783.3M | CN¥727.4M | CN¥240.8M |
| Earnings per share | CN¥0.24 | CN¥0.44 | −CN¥0.53 | CN¥0.50 | CN¥0.16 |
| EBITDA | CN¥846.6M | CN¥1.2B | −CN¥331.5M | CN¥1.4B | CN¥726.6M |
| Total assets | CN¥16.6B | CN¥17.3B | CN¥19.2B | CN¥20.8B | CN¥19.1B |
| Total debt | CN¥2.1B | CN¥3.0B | CN¥3.8B | CN¥6.5B | CN¥5.7B |
| Cash and short-term investments | CN¥2.8B | CN¥2.6B | CN¥2.3B | CN¥3.5B | CN¥3.9B |
| Shareholders' equity | CN¥12.0B | CN¥12.1B | CN¥11.9B | CN¥12.3B | CN¥11.4B |
| Operating cash flow | CN¥1.7B | CN¥2.2B | CN¥398.2M | −CN¥756.6M | −CN¥6.6M |
| Free cash flow | CN¥1.6B | CN¥2.0B | −CN¥46.7M | −CN¥979.0M | −CN¥200.5M |
| Capital expenditure | −CN¥121.1M | −CN¥202.8M | −CN¥444.9M | −CN¥222.4M | −CN¥193.9M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CNY; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| HUTCHMED (China) | 0013.HK | HK$23.16 | HK$20.13B |
| Shanghai Conant Optical | 2276.HK | HK$37.18 | HK$17.98B |
| CanSino Biologics | 6185.HK | HK$36.80 | HK$12.88B |
| Consun Pharmaceutical | 1681.HK | HK$15.02 | HK$12.60B |
| Ab&B Bio-Tech Co. Ltd. JS | 2627.HK | HK$29.32 | HK$10.56B |
| Everest Medicines | 1952.HK | HK$29.56 | HK$10.39B |
| Shandong Xinhua Pharmaceutical | 0719.HK | HK$5.83 | HK$8.78B |
| SSY | 2005.HK | HK$2.83 | HK$8.17B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Shenzhen Hepalink Pharmaceutical Group from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 9989 and buy
Find Shenzhen Hepalink Pharmaceutical Group by name or by its ticker, 9989, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in Shenzhen Hepalink Pharmaceutical Group from India
What Shenzhen Hepalink Pharmaceutical Group does
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. Shenzhen Hepalink Pharmaceutical Group operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Shenzhen Hepalink Pharmaceutical Group stock from India?
Yes. Indian residents and NRIs can buy Shenzhen Hepalink Pharmaceutical Group (9989) shares directly through Paasa. Shenzhen Hepalink Pharmaceutical Group is listed on the Hong Kong Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Shenzhen Hepalink Pharmaceutical Group share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$4.03 a share, size the order by the lot, not by the share.
How are Shenzhen Hepalink Pharmaceutical Group dividends taxed for Indian investors?
Shenzhen Hepalink Pharmaceutical Group trades on the Hong Kong Stock Exchange but is domiciled in China, so any withholding on its dividends follows that country's rules rather than those of Hong Kong. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Shenzhen Hepalink Pharmaceutical Group shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.